Experimental simvastatin-induced myopathy in rabbits

Area of Science:

• Biochemistry
• Pharmacology
• Neurology

Background:

• Statins, including simvastatin, are widely used to lower cholesterol by inhibiting HMG-CoA reductase.
• Statin-induced myopathy is a known adverse effect, but its precise mechanisms remain under investigation.
• Understanding the pathophysiology of statin-induced myopathy is crucial for patient safety and treatment optimization.

Purpose of the Study:

• To investigate the effects of simvastatin on muscle tissue in a rabbit model.
• To identify specific pathological changes associated with simvastatin administration.
• To explore potential mechanisms underlying simvastatin-induced myopathy.

Main Methods:

• Experimental myopathy was induced in rabbits via oral administration of simvastatin (50 mg/kg/day) for two weeks.
• Serum creatine kinase (CK) levels were measured to assess muscle damage.
• Muscle tissue was examined histopathologically for signs of degeneration or necrosis.
• Electromyography (EMG) was performed to detect myotonic discharges.

Main Results:

• Elevated serum CK levels were observed in 5 out of 7 rabbits treated with simvastatin.
• Histopathological examination revealed degenerating or necrotic muscle fibers in 3 rabbits.
• Electromyography identified myotonic discharges in 2 rabbits, indicating neuromuscular abnormalities.
• The combination of clinical, biochemical, and electrophysiological findings suggests simvastatin-induced muscle membrane lesions.

Conclusions:

• Simvastatin can induce experimental myopathy in rabbits, characterized by muscle fiber damage and elevated CK levels.
• The presence of myotonic discharges in conjunction with necrosis and elevated CK suggests a primary effect on the muscle surface membrane.
• These findings contribute to understanding the pathogenesis of statin-induced myopathy and highlight the importance of monitoring muscle health in patients taking simvastatin.